Muhammad Ibrahima,
Mumtaz Ali*a,
Sobia Ahsan Halimb,
Abdul Latif*a,
Manzoor Ahmada,
Sajid Alia,
SameeUllaha,
Ajmal Khanb,
Alany Ingrido Rebierioc,
Jalal Uddind and
Ahmed Al-Harrasi*b
aDepartment of Chemistry, University of Malakand, Dir Lower, Chakdara 18800, Khyber Pakhtunkhwa, Pakistan. E-mail: mumtazphd@gmail.com
bNatural and Medical Sciences Research Centre, University of Nizwa, PO Box 33, 616 Birkat Al Mauz, Nizwa, Oman. E-mail: ajmalkhan@unizwa.edu.com; aharrasi@unizwa.edu.com
cDepartment of Chemistry, Federal University of São Carlos, Rod. Washington Luís, Km 265, São Carlos 13565-905, Brazil
dDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, 62529, Kingdom of Saudi Arabia
First published on 24th August 2023
In current research, two functional components, i.e., hydrazone and bisphenol sulfide were combined to get useful supramolecules in medicinal chemistry. Herein 25 new 4,4′-thiodiphenol bis-acylhydrazones were synthesized in good to excellent yields. Initially ethyl-2-chloroacetate was reacted with 4,4′-thiodiphenol, which was further reacted with excess hydrazine hydrate to produce 2,2′-((thiobis(4,1-phenylene))bis(oxy))di(acetohydrazide), which was then combined with various aromatic and aliphatic aldehydes to get the desired products (hydrazones, 4a–4y). The synthesized supramolecules were characterized by contemporary spectroscopic techniques such as 1H NMR, 13C NMR, and mass spectroscopy. The synthetic compound's cholinesterase blocking activity was tested against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes where compounds 4n, and 4h showed excellent inhibitory potential for AChE, while 4b, and 4h, demonstrated most potent inhibition of BChE. The starting compound (SM3) and compounds 4h and SM3 depicted excellent dual inhibitory capabilities for both enzymes. The chemical basis of anticholinesterase activity was investigated using a structure-based molecular docking approach. The biological significance and the ease of synthesis of this class of compounds should be considered in therapeutic development for Alzheimer's disease treatments.
The sulfide group and the Schiff's bases (hydrazide-hydrazones) are two important pharmacophores that have drawn medicinal chemists to create novel medications.3 The hydrazones of aromatic carbonyl (aldehydes and ketones) compounds, have a strong conjugated system, excellent stability,4 and are significant intermediates in the field of organic chemistry.5 The unusual biological potential of Schiff's bases, including antibacterial7 anti-inflammatory,10 anti-tumor,9 anticancer,6 analgesic11 and antifungal8 properties, has received a lot of attention recently. Researchers are attracted to the synthesis of hydrazide-hydrazone derivatives, because of intriguing biological activities of this pharmacophore like anti-proliferative,12 potential inhibitor to different enzymes,13 anti-convulsant,14 anti-microbial,18 anti-malarial,16 anti-leishmanial,15 anti-mycobacterial,17 anti-viral,21 anti-HIV,20 anti-pyretic23 and anti-protozoal,24 anti-trypanosomal,22 anti-HIV,25 anti-depressant,26 anti-tubercular,19 and anti-oxidant27 activities which are crucial to organic and medicinal chemistry. Several commercially marketed hydrazide-hydrazone derivatives are available, for example nifurtimox (treats Chagas disease),28 nifuroxazide (antibiotic to treat colitis and diarrhea), and nitrofurazone (antimicrobial agent), furazolidone (antibacterial agent and monoamine oxidase inhibitor), and nitrofurantoin (antibacterial medicine to treat urinary tract infections)1 which shows the importance of hydrazide-hydrazone scaffold.29
In an effort to enhance the bio-chemical properties of compounds, the sulfide group and hydrazide-hydrazones were incorporated into a single molecule. This study sought to find new compounds with improved anticholinesterase activities30–32 by synthesizing a series of bis(acylhydrazones) from bisphenol sulfide. Additionally, a well-known structure-based drug design approach i.e., molecular docking was used to investigate the binding behavior of the highest, moderate, and least active molecules against both studied enzymes.
Scheme 1 Thiodiphenol (1) is esterified to produce diethyl 2,2′-((thiobis(4,1-phenylene))bis(oxy))diacetate (2). |
In the process of being synthesized, 2,2′-((thiobis(4,1-phenylene))bis(oxy))di (acetohydrazide) (3) involved the reaction of 2,2′-((thiobis(4,2-phenylene))bis(oxy))diacetate (2) with an excess of hydrazine hydrate. This reaction was carried out in anhydrous methanol as the solvent (Scheme 2).35
The hydrazide (3) was utilized in reactions with several aldehydes, both aromatic and aliphatic, in either DMF or ethyl alcohol which led to the synthesis of the matching bis(acylhydrazones) (4a–4y) with high yields ranging from 80% to 90% (Fig. 1). While considering the overall yields of the products obtained using different solvents, it can be inferred that DMF surpasses ethanol as a solvent for this reaction. This is likely due to the complete solubility of the hydrazide (3) in DMF. The enhanced solubility of the hydrazides in DMF makes it straightforward to separate the hydrazones by dissolving the reaction mixture in ice-cold water (Scheme 3). A collection of twenty-five (25) different bis(acylhydrazones) were prepared (Fig. 1) and their medicinal properties were evaluated in vitro by targeting acetyl and butyrylcholinesterase enzymes (Table 1).
Compounds | AChE | BChE |
---|---|---|
IC50 (μM) ± SD | IC50 (μM) ± SD | |
a NA = not active, SD = standard deviation. | ||
4a | NA | NA |
4b | NA | 14.7 ± 0.8297 |
4c | 148.1 ± 0.7700 | 93.3 ± 0.8208 |
4d | 67.0 ± 0.8623 | 44.7 ± 0.8461 |
4e | 74.2 ± 0.7970 | 142.5 ± 0.7698 |
4f | 131.4 ± 0.8634 | 117.1 ± 0.8046 |
4g | 36.3 ± 0.7874 | 239.2 ± 0.8209 |
4h | 27.8 ± 0.7232 | 19.0 ± 0.8625 |
4i | 45.4 ± 0.6736 | 65.7 ± 0.7662 |
4j | 39.1 ± 0.7811 | 84.6 ± 0.7276 |
4k | 47.3 ± 0.7912 | 75.1 ± 0.8628 |
4l | 33.5 ± 0.9318 | 109.4 ± 0.8708 |
4m | 51.1 ± 0.7283 | 60.3 ± 0.6995 |
4n | 25.7 ± 0.8137 | 48.6 ± 0.6727 |
4o | 40.2 ± 0.8223 | 55.4 ± 0.7870 |
4p | 49.1 ± 0.6934 | 110.2 ± 0.8135 |
4q | 192.8 ± 0.6493 | 119.6 ± 0.6420 |
4r | NA | NA |
4s | 91.5 ± 0.6153 | 36.4 ± 0.7022 |
4t | 37.7 ± 0.6853 | 78.9 ± 0.6850 |
4u | 235.1 ± 0.7335 | 113.5 ± 0.6950 |
4v | NA | NA |
4w | NA | NA |
4x | 186.3 ± 0.8761 | 103.1 ± 0.8765 |
4y | 122.6 ± 0.9429 | 101.1 ± 0.9378 |
SM2 | NA | NA |
SM3 | 23.1 ± 0.6540 | 21.8 ± 0.8761 |
Galantamine | 29.5 ± 0.9036 | 27.8 ± 0.8740 |
Among all the compounds, SM3, 4n, 4h, 4l, 4g, 4t, 4j and 4o showed good inhibitory activity for AChE with IC50 value in range of 23.1 to 40.2 μM, while 4b, 4h, SM3, 4s, 4d, and 4n effectively inhibited the activity of BChE with IC50 ranging from 14.7 to 48.6 μM. We observed that compound 4h and the starting molecule SM3 have dual inhibitory properties for both AChE and BChE (Table 1). A well-known cholinesterase inhibitor, galantamine was used as a positive control which bears IC50 values of 29.5 μM and 27.8 μM for AChE and BChE, respectively. These findings suggests that bis(acylhydrazones), particularly SM3 and 4h holds promise as alternative therapeutic agents for the treatment of Alzheimer's disease.
Before docking our synthesized compounds, the standard inhibitor, galantamine was manually docked into the active site of Electric eel AChE (https://alphafold.com/entry/O42275) and Equine BChE (https://alphafold.com/entry/P81908) to deduce its binding mode in these enzymes. The electric eel AChE and equine BChE structures was selected for docking studies because these sources were used in the in vitro experiments. Several residues including Asp96, Trp108, Gly142-Gly144, Tyr146, Ser147, Tyr155, Glu224, Ser225, Trp258, Phe313, Phe315, Tyr355, Phe356, Tyr359, Glu352, and His494, Gly495 constitutes the active site of electric eel AChE, where galantamine binds with the side chain of Glu224 through hydrogen bond, while Trp108 provides hydrophobic interactions to galantamine. The active site of equine BChE is constituted by Asp70, Ser79, Trp82, Asn83, Tyr114, Gly115-Gly117, Phe118, Gly121, Tyr128, Glu197, Ser198, Ala199, Trp231, Phe329, Tyr332, His438, Gly439, and Ile442. In the active site of equine BChE, Glu197, and Gly116 mediates hydrogen bonds with the –OH group of galantamine. When our selected inhibitors were docked into the active site of AChE, these molecules showed excellent binding interactions and the bisphenol sulfide moiety of these molecules resides in the middle of AChE active site, while one of the acylhydrazone moieties is located at the gorge of the active site, and the other acylhydrazone moiety is located near the entrance of AChE active site. The acylhydrazone moieties of most active inhibitor of AChE, SM3 mediates strong hydrogen bonds with multiple residues including Gly311, Trp108, and Arg314, these multiple hydrogen bonding within the active site is responsible for the higher AChE inhibitory activity of SM3. Similarly, one of the acyl hydrazone moiety of 4h and 4i formed H-bond with side chain of Ser147 and Tyr155, respectively, while their substituted methoxy-phenol ring forms hydrophobic interaction with the side chain of Trp108 in the active site of AChE. The less hydrogen bond interactions of 4h and 4i with the active site residues of AChE as compared to SM3 leads to the moderate activity of 4h and 4i. Likewise, the compound 4k mediates H-bond and hydrophobic interaction with Ser147 and Trp108 through its acylhydrazone and its linked dicholorphenyl ring, respectively. In addition, the other acylhydrazone also forms H-bond with backbone of Phe313 at the entrance of the active site. While the least active molecule, 4q mediates only bidentate interaction with Ser149 and Tyr155. The compounds possess docking scores in range of −7.73 to −3.04 kcal mol−1, where both highly active compounds, SM3 (−7.73kcal mol−1) and 4h (−7.18 kcal mol−1) exhibited higher docking score than galantamine (−5.69 kcal mol−1) which is in good agreement with the IC50 values of these compounds. The binding interactions of the selected compounds are shown in Fig. 2A.
The compound 4h shows excellent inhibitory potency for BChE, when docked into the active site of BChE, this compound reflects multiple interactions with Asp283, Tyr332, and Trp82. We observed that one of the substituted methoxyphenol group formed H-bond with the side chain of Asp283 instead of the acylhydrazone moiety of the compound. While the diphenylsulfane ring forms hydrophobic interaction (π–π) with Trp82, similarly the other substituted acylhydrazone moiety formed hydrophobic interaction (π–H) with Tyr332. In compound SM3, both the acetohydrazide groups formed strong H-bonds with the side chains of Ser287 and Gly115. Interestingly, the diphenylsulfane of compounds 4i, 4k and 4q accepts H-bonds with the side chain of Ser198, while the diphenylsulfane of 4i and 4k and the substituted cumene of 4q formed hydrophobic interactions with trp82, Phe329, and Asn68, respectively. It is clear that due to the higher number of binding interactions with the residues of active site, these molecules exhibits high inhibitory activity, while the activity of compounds are reduced when their binding interactions are reduced. The compounds' docking scores vary from −9.52 to −3.36 kcal mol−1 (Table 2). Again, we obtained higher docking scores of 4h (−9.52 kcal mol−1), SM3 (−7.15 kcal mol−1) and 4i (−6.98 kcal mol−1) as compared to galantamine (−6.66 kcal mol−1) while 4k and 4q bears lesser docking scores than the standard inhibitor. The molecular interactions of compounds 4h, SM3, 4i, 4k, and 4q are summarized in Table 2 and presented in Fig. 2B.
Compounds | Docking score (kcal mol−1) | AChE-ligands interactions | |||
---|---|---|---|---|---|
LA | RA | Interaction | Distance (Å) | ||
a LA = ligand atom, RA = receptor Atom, HBA = hydrogen bond acceptor, HBD = hydrogen bond donor. | |||||
SM3 | −7.73 | N31 | O-GLY311 | HBD | 2.09 |
N38 | O-TRP108 | HBD | 2.54 | ||
O30 | N-ARG314 | HBA | 2.19 | ||
4h | −7.18 | N28 | OG-SER147 | HBD | 2.52 |
6-Ring | 6-Ring-TRP108 | π–π | 2.81 | ||
Galantamine | −5.69 | O18 | OE2-GLU224 | HBD | 2.70 |
4k | −5.41 | N36 | OG-SER147 | HBD | 2.87 |
O30 | N-PHE313 | HBA | 2.18 | ||
6-Ring | 6-Ring-TRP108 | π–π | 2.61 | ||
4i | −5.39 | O38 | OH-TYR155 | HBA | 2.44 |
6-Ring | 5-Ring-TRP108 | π–π | 2.90 | ||
6-Ring | 6-Ring-TRP108 | π–π | 2.65 | ||
4q | −3.04 | O38 | N-SER149 | HBA | 2.13 |
O38 | OH-TYR155 | HBA | 2.10 |
Compounds | BChE IC50 (μM) | BChE-ligands interactions | |||
---|---|---|---|---|---|
4h | −9.52 | O72 | OD1-ASP283 | HBD | 2.38 |
O72 | OD2-ASP283 | HBD | 2.30 | ||
C42 | 6-Ring-TYR332 | H–π | 2.70 | ||
6-Ring | 5-Ring-TRP82 | π–π | 2.61 | ||
SM3 | −7.15 | N41 | O-SER287 | HBD | 2.14 |
O30 | N-GLY115 | HBA | 2.39 | ||
4i | −6.98 | S11 | OG-SER198 | HBA | 2.12 |
C8 | 5-Ring-TRP82 | H–π | 2.81 | ||
Galantamine | −6.66 | O18 | OE2-GLU197 | HBD | 2.76 |
O18 | N-GLY116 | HBA | 2.04 | ||
4k | −4.12 | S11 | OG-SER198 | HBA | 2.51 |
6-Ring | CE1-PHE329 | H–π | 2.94 | ||
4q | −3.36 | S11 | OG-SER198 | HBA | 2.52 |
6-Ring | CB-ASN68 | H–π | 2.56 |
Yield: 8 g (97%); white solid; mp 107–109 °C.
HR-MS (EIMS): m/z [M + H]+ calcd for C20H22O6S: 390.4500, found: 390.1031.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 1.230 (t, J = 7.0 Hz, 6H, 2 –CH3), 4.902 (q, J = 7.5 Hz, 4H, 2 –CH2–), 4.6 s (4H, 2 –CH2–), 7.16 (d, J = 8.2 Hz, 4H, Ar–H), 7.38 (d, J = 8.2 Hz, 4H, Ar–H).
13C NMR (600.153 MHz, DMSO-d6): (δ ppm): 168.49, 161.16, 134.04, 129.30, 115.45, 64.68, 60.85, 51.96, 13.99.
Yield: 90% (5581 mg); white solid; mp 227–229 °C. HR-MS (EIMS): m/z [M + H]+ calcd for C16H18N4O4S: 362.4020, found: 362.1020.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 9.08 (s, 4H, 2-NH2), 4.22 (s, 2H, 2-NH–), 4.590 (s, 4H, 2-CH2–), 7.160 (d, J = 8.2 Hz, 4H, Ar–H), 7.381 (d, J = 8.2 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.11, 163.66, 134.54, 129.80, 115.95, 66.36.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H24N6O8S: 628.1400, found: 628.2525.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.686 (s, 2H, 2-NH–), 4.733 (s, 4H, 2-CH2–), 8.428, 8.408 (s, 2H, 2 CH–), 6.999, 7.053 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.510, 7.558 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.929, 7.981 (d, d, J = 8.4 Hz, 4H, Ar–H), 8.252, 8.283 (d, d, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.52, 164.85, 162.33, 157.37, 147.98, 147.82, 145.52, 141.54, 140.47, 140.32, 132.71, 128.11, 127.95, 127.36, 127.26, 124.08, 124.02, 115.16, 114.99, 66.60, 64.85, 35.81, 30.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H24Cl2N4O4S: 606.0900, found: 606.1993.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.687 (s, 2H, 2-NH–), 4.689 (s, 4H, 2-CH2–), 8.311, 7.997 (s, 2H, 2 CH–), 6.980, 7.046 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.484, 7.506 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.542, 7.566 (d, d, J = 8.4 Hz, 4H, Ar–H), 7.705, 7.740 (d, d, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.15, 164.42, 162.33, 157.47, 157.30, 156.93, 146.67, 142.59, 134.65, 134.41, 133.11, 132.98, 132.67, 128.96, 128.90, 128.80, 127.34, 127.28, 127.24, 115.15, 114.96, 66.62, 64.80, 35.80, 30.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C32H26N4O6S: 594.1600, found: 594.2686.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.686 (s, 2H, 2-NH–), 10.015 (s, 2H, 2CHO), 4.723 (s, 4H, 2-CH2–), 8.403, 8.085 (s, 2H, 2 CH–), 6.997, 7.054 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.523, 7.558 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.896, 7.910 (d, d, J = 8.4 Hz, 4H, Ar–H), 7.918, 7.945 (d, d, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 192.72, 169.39, 164.67, 162.33, 146.57, 142.55, 139.66, 139.51, 136.74, 129.96, 129.93, 127.68, 127.52, 127.36, 127.30, 127.25, 115.17, 114.99, 66.64, 64.85, 35.80, 30.81.
HR-MS (EIMS): m/z [M + H]+ calcd for C36H38N4O10S: 718.2300, found: 718.3526.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.599 (s, 2H, 2-NH–), 4.691 (s, 4H, 2-CH2–), 3.804 (s, 6H, 2-CH3), 3.688 (s, 12H, 4-CH3), 8.256, 7.925 (s, 2H, 2 CH–), 6.977, 7.051 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.521, 7.559 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.012 (s, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.14, 164.22, 153.19, 148.02, 143.66, 139.38, 139.17, 129.62, 129.54, 127.38, 127.31, 127.27, 127.20, 115.17, 114.91, 104.43, 104.29, 66.64, 64.89, 60.15, 55.99.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H26N4O6S: 570.1600, found: 570.2664.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.368 (s, 2H, 2-NH–), 9.934 (s, 2H, 2-OH), 4.723 (s, 4H, 2-CH2–), 8.214, 7.903 (s, 2H, 2 CH–), 6.972, 7.046 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.505, 7.518 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.798, 6.812 (d, d, J = 8.4 Hz, 4H, Ar–H), 7.541, 7.556 (d, d, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.68, 163.88, 162.33, 159.53, 159.32, 157.51, 157.43, 157.04, 156.97, 148.30, 144.18, 133.14, 132.98, 132.63, 132.45, 128.93, 128.69, 127.37, 127.32, 127.28, 127.22, 125.09, 125.03, 115.72, 115.70, 115.16, 114.92, 66.67, 64.78, 35.81, 30.81.
HR-MS (EIMS): m/z [M + H]+ calcd for C38H30N4O4S: 638.2000, found.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.666, 11.648 (s, 2H, 2-NH–), 4.755 (s, 4H, 2-CH2–), 9.010, 8.687 (s, 2H, 2 CH–), 7.023, 7.110 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.535, 7.550 (d, d, J = 8.2 Hz, 4H, Ar–H), 8.799, 8.818 (dd, J = 8.4 Hz, 2H, Ar–H), 8.012, 8.022 (ddd, J = 8.4 Hz, 2H, Ar–H), 8.614, 8.628 (dd, J = 8.4 Hz, 2H, Ar–H), 7.910, 7.999 (dd, J = 8.4 Hz, 2H, Ar–H), 7.565, 7.591 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.601, 7.659 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.635, 7.659 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.68, 163.88, 162.33, 159.53, 159.32, 157.51, 157.43, 157.04, 156.97, 148.30, 144.18, 133.14, 132.98, 132.63, 132.45, 128.93, 128.69, 127.37, 127.32, 127.28, 127.22, 125.09, 125.03, 115.74, 115.70, 115.16, 114.92, 66.67, 64.78, 35.81, 30.81.
HR-MS (EIMS): m/z [M + H]+ calcd for C34H34N4O8S: 658.2100, found: 658.3287.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.418, 11.378 (s, 2H, 2-NH–), 9.448 (s, 2H, 2-OH), 4.653 (s, 4H, 2-CH2–), 1.307, 1.350 (t, J = 7.0 Hz, 6H, 2-CH3), 4.029, 4.040 (q, J = 7.5 Hz, 4H, 2-CH2–) 8.188, 7.783 (s, 2H, 2 CH–), 7.046, 7.079 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.532, 7.569 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.506, 7.519 (d, J = 8.4 Hz, 2H, Ar–H), 7.240, 7.250 (dd, J = 8.4 Hz, 2H, Ar–H), 6.953, 6.957 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.77, 163.89, 162.33, 157.54, 149.36, 149.08, 148.55, 147.19, 147.12, 144.27, 127.37, 127.30, 127.26, 127.19, 125.46, 122.10, 121.33, 115.62, 115.57, 115.16, 114.90, 110.96, 110.51, 66.68, 6486, 63.91, 35.80, 30.80, 14.74, 14.71.
HR-MS (EIMS): m/z [M + H]+ calcd for C32H30N4O8S: 630.1800, found: 630.2939.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.525 (s, 2H, 2-NH–), 10.730 (s, 2H, 2-OH), 4.795 (s, 4H, 2-CH2–), 3.811 (s, 6H, 2-OCH3) 8.569, 8.334 (s, 2H, 2 CH–), 7.124, 7.309 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.509, 7.851 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.965, 6.992 (d, J = 8.4 Hz, 2H, Ar–H), 6.795, 6.853 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.024, 7.066 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.72, 164.21, 157.48, 156.97, 156.89, 148.22, 148.02, 147.98, 147.13, 146.01, 141.36, 133.23, 133.05, 127.41, 127.35, 127.30, 127.24, 120.63, 120.46, 119.21, 119.09, 118.93, 117.91, 115.19, 114.94, 113.96, 66.57, 64.86, 55.89.
HR-MS (EIMS): m/z [M + H]+ calcd for C32H30N4O8S: 630.1800, found: 630.2958.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.429, 11.392 (s, 2H, 2-NH–), 9.570 (s, 2H, 2-OH), 4.658 (s, 4H, 2-CH2–), 3.800 (s, 6H, 2-OCH3) 8.203, 7.940 (s, 2H, 2 CH–), 6.957, 6.970 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.519, 7.570 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.258, 7.269 (d, J = 8.4 Hz, 2H, Ar–H), 7.048, 7.088 (dd, J = 8.4 Hz, 2H, Ar–H), 6.808, 6.820 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.78, 163.89, 162.34, 159.46, 157.55, 157.46, 157.05, 156.96, 149.12, 148.84, 148.54, 148.06, 147.98, 144.27, 132.98, 132.43, 127.37, 127.31, 127.27, 127.20, 125.50, 125.46, 122.20, 121.36, 115.55, 115.47, 115.17, 114.91, 109.69, 109.12, 66.68, 64.85, 55.63, 55.60, 35.81, 20.21.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H26N4O8S: 602.1500, found: 602.2595.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.257 (s, 2H, 2-NH–), 10.038 (s, 2H, 2-OH), 4.684 (s, 4H, 2-CH2–), 8.413, 8.172 (s, 2H, 2 CH–), 6.967, 7.058 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.532, 7.575 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.474, 7.488 (d, J = 8.4 Hz, 2H, Ar–H), 6.303, 6.337 (dd, J = 8.4 Hz, 2H, Ar–H), 7.267, 7.281 (d, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm: 172.69, 168.26, 163.83, 162.29, 160.67, 159.67, 158.14, 157.14, 149.55, 142.67, 133.03, 131.21, 127.39, 127.33, 127.28, 115.19, 114.92, 112.07, 107.86, 102.68, 102.44, 66.85, 65.42, 35.81, 30.72.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H22Cl4N4O4S: 674.0100, found: 674.1286.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.866, (s, 2H, 2-NH–), 4.715 (s, 4H, 2-CH2–), 8.703, 8.342 (s, 2H, 2 CH–), 6.992, 7.061 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.500, 7.564 (d, d, J = 8.2 Hz, 4H, Ar–H), 8.028, 8.043 (dd, J = 8.4 Hz, 2H, Ar–H), 7.952, 7.967 (dd, J = 8.4 Hz, 2H, Ar–H), 7.12 (d, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.30, 164.66, 157.37, 142.86, 138.86, 135.24, 135.00, 133.97, 133.68, 132.70, 130.58, 130,41, 129.41, 129.38, 128.33, 128.17, 128.07, 127.97, 127.40, 127.35, 127.28, 127.24, 115.19, 114.99, 66.69, 64.84, 35.86, 14.30.
HR-MS (EIMS): m/z [M + H]+ calcd for C38H44N6O4S: 680.3100, found: 680.4315.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.272, 11.216 (s, 2H, 2-NH–), 4.646 (s, 4H, 2-CH2–), 8.143, 7.843 (s, 2H, 2 CH–), 1.081, 1.100 (t, J = 7.0 Hz, 12H, 4-CH3), 3.297, 3.373 (q, J = 7.5 Hz, 8H, 4-CH2–), 6.966, 7.048 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.405, 7.519 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.660, 6.688 (dd, J = 8.4 Hz, 4H, Ar–H), 7.544, 7.570 (dd, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 189.48, 168.36, 163.50, 148.97, 148.86, 148.78, 144.74, 128.85, 128.56, 127.36, 127.30, 127.22, 120.44, 115.15, 114.90, 111.11, 110.63, 66.71, 64.80, 43.75, 12.45.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H26N4O6S: 570.1600, found: 570.2672.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.542, 11.523 (s, 2H, 2-NH–), 4.679 (s, 4H, 2-CH2–), 8.239, 8.229 (s, 2H, 2 CH–), 9.611 (s, 2H, 2-OH), 7.094, 7.148 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.920, 7.940 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.966, 6.980 (d, J = 8.4 Hz, 2H, Ar–H), 6.806, 6.819 (dd, J = 8.4 Hz, 2H, Ar–H), 7.212, 7.238 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.512, 7.576 (ddd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.95, 164.26, 162.33, 157.70, 157.66, 157.47, 157.40, 156.95, 148.06, 144.08, 135.40, 135.24, 133.17, 133.00, 132.68, 132.52, 129.89, 127.39, 127.34, 127.31, 127.26, 118.86, 118.45, 117.56, 117.31, 115.16, 114.92, 112.77, 112.71, 66.65, 64.74, 35.80, 30.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C34H34N4O8S: 658.2100, found: 658.5057.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.466 (s, 2H, 2-NH–), 4.672 (s, 4H, 2-CH2–), 8.249, 7.940 (s, 2H, 2 CH–), 3.783 (s, 6H, 2-OCH3), 3.789 (s, 6, 2-OCH3), 7.050, 7.193 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.570, 7.940 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.974, 7.000 (dd, J = 8.4 Hz, 2H, Ar–H), 7.289, 7.313 (dd, J = 8.4 Hz, 2H, Ar–H), 7.520, 7.545 (d, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.90, 164.02, 162.33, 157.55, 157.47, 157.04, 156.96, 150.88, 150.64, 149.10, 149.07, 148.21, 143.92, 133.16, 132.99, 132.44, 127.38, 127.31, 127.26, 127.21, 126.83, 126.79, 121.95, 121.27, 115.17, 114.92, 111.55, 108.77, 108.40, 66.68, 64.88, 5561, 55.51, 38.30, 30.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C34H34N4O8S: 658.2100, found: 658.3267.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.458, 11.409 (s, 2H, 2-NH–), 4.636 (s, 4H, 2-CH2–), 8.574, 8.249 (s, 2H, 2 CH–), 3.783 (s, 6H, 2-OCH3), 3.789 (s, 6H, 2-OCH3), 7.032, 7.046 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.509, 7.569 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.581, 6.616 (d, J = 8.4 Hz, 2H, Ar–H), 6.954, 6.968 (dd, J = 8.4 Hz, 2H, Ar–H), 7.744, 7.776 (d, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.66, 163.83, 162.56, 162.35, 159.24, 159.06, 157.52, 157.44, 143.55, 139.65, 132.62, 127.35, 127.30, 127.21, 126.76, 115.14, 114.93, 106.52, 106.44, 98.34, 98.17, 66.63, 64.83, 55.82, 55.48, 35.81, 30.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C32H30N4O6S: 598.1900, found: 598.3018.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.615, 11.567 (s, 2H, 2-NH–), 4.680 (s, 4H, 2-CH2–), 8.698, 8.364 (s, 2H, 2 CH–), 3.861 (s, 6H, 2-OCH3), 7.058, 7.117 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.826, 7.813 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.983, 7.025 (dd, J = 8.4 Hz, 2H, Ar–H), 7.023, 7.428 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.523, 7.579 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.875, 7.863 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.13, 164.34, 159.57, 147.92, 143.70, 135.57, 135.43, 132.65, 129.98, 129.94, 127.39, 127.33, 127.28, 127.23, 120.09, 119.63, 116.37, 115.92, 115.17, 114.94, 111,64, 111.34, 66.65, 64.83, 55.21.
HR-MS (EIMS): m/z [M + H]+ calcd for C36H38N4O4S: 622.2600, found: 622.3745.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.544 (s, 2H, 2-NH–), 4.679 (s, 4H, 2-CH2–), 8.303, 7.982 (s, 2H, 2 CH–), 1.194–1.205 (d, J = 7.4 Hz, 12H, 4-CH3), 2.980 (heptet, J = 7.5 Hz, 2H, 2-CH–), 6.966, 7.055 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.512, 7.572 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.602, 7.623 (d, d, J = 8.4 Hz, 4H, Ar–H), 7.295, 7.320 (d, d, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.95, 164.18, 157.50, 157.43, 156.96, 150.83, 150.60, 148.03, 142.93, 133.16, 132.66, 132.50, 131.84, 131.72, 127.38, 127.33, 127.26, 127.05, 126.83, 126.78, 115.16, 114.93, 66.66, 64.81, 33.40, 33.38, 23.68.
HR-MS (EIMS): m/z [M + H]+ calcd for C26H22N4O4S3: 550.0800, found: 550.1864.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.550 (s, 2H, 2-NH–), 4.668 (s, 4H, 2-CH2–), 8.549, 8.190 (s, 2H, 2 CH–), 6.943, 7.047 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.439, 7.521 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.116, 7.130 (dd, J = 8.4 Hz, 2H, Ar–H), 7.631, 7.663 (dd, J = 8.4 Hz, 2H, Ar–H), 7.535, 7.544 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.65, 164.15, 157.44, 156.99, 156.92, 143.17, 139.03, 138.86, 138.67, 133.02, 132.15, 130.56, 139.12, 128.62, 127.94, 127.89, 127.39, 127.32, 127.27, 115.18, 114.98, 66.68, 64.57, 38.90, 35.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H24F2N4O4S: 574.1500, found: 574.2565.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.600 (s, 2H, 2-NH–), 4.687 (s, 4H, 2-CH2–), 8.335, 8.007 (s, 2H, 2 CH–), 6.993, 7.052 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.510, 7.560 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.258, 7.279 (d, d, J = 8.4 Hz, 4H, Ar–H), 7.750, 7.787 (d, d, J = 8.4 Hz, 4H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.08, 164.33, 164.03, 162.38, 162.24, 157.49, 157.41, 156.94, 146.88, 142.73, 133.00, 132.67, 132.49, 130.77, 130.66, 129.38, 129.32, 129.20, 129.14, 127.34, 127.28, 127.24, 127.01, 116.01, 115.94, 115.86, 115.80, 115.16, 114.95, 66.65, 64.81, 38.30, 35.80, 30.40.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H26N4O6S: 570.6200, found: 570.2663.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.819, 11.535 (s, 2H, 2-NH–), 4.720 (s, 4H, 2-CH2–), 8.560, 8.306 (s, 2H, 2 CH–), 11.044 and 10.049 (s, 2H, 2-OH), 6.969, 7.055 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.511, 7.583 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.839, 6.851 (dd, J = 8.4 Hz, 2H, Ar–H), 6.864, 6.914 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.223, 7.297 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.699, 7.712 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.72, 164.25, 157.41, 156.98, 156.90, 156.44, 148.37, 141.52, 133.24, 133.06, 131.54, 131.23, 129.34, 127.41, 127.35, 127.30, 127.24, 126.58, 120.05, 119.44, 119.40, 118.65, 116.42, 116.17, 112.20, 114.95, 66.56,64.89, 38.40, 35.90, 30.80.
HR-MS (EIMS): m/z [M + H]+ calcd for C30H24Cl2N4O4S: 606.5100, found: 606.2000.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.851, 11.778 (s, 2H, 2-NH–), 4.710 (s, 4H, 2-CH2–), 8.749, 8.397 (s, 2H, 2 CH–), 6.982, 7.067 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.512, 7.556 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.570, 7.585 (dd, J = 8.4 Hz, 4H, Ar–H), 7.409, 7.448 (ddd, J = 8.4 Hz, 2H, Ar–H), 7.956, 8.030 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.25, 164.59, 157.39, 143.91, 139.90, 133.28, 132.98, 132.69, 131.65, 131.41, 131.29, 129.96, 129.91, 127.67, 127.63, 127.41, 127.35, 127.30, 127.24, 127.11, 126.98, 115.20, 114.98, 66.69, 64.85, 35.80, 30.70.
HR-MS (EIMS): m/z [M + H]+ calcd for C28H26N4O6S: 546.6000, found: 546.0000.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.453, 11.436 (s, 2H, 2-NH–), 4.657 (s, 4H, 2-CH2–), 8.123, 7.810 (s, 2H, 2 CH–), 2.324 (s, 6H, 2-CH3), 6.936, 7.028 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.499, 7.571 (d, d, J = 8.2 Hz, 4H, Ar–H), 6.244 (dd, J = 8.4 Hz, 2H, Ar–H), 6.783, 6.795 (dd, J = 8.4 Hz, 2H, Ar–H).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.67, 164.08, 157.46, 154.71, 154.55, 147.71, 147.53, 137.67, 134.17, 127.38, 127.32, 127.28, 127.23, 115.64, 115.39, 115.18, 114.92, 108.59, 66.72, 64.62, 13.56, 13.49.
HR-MS (EIMS): m/z [M + H]+ calcd for C28H38N4O4S: 526.7000, found: 526.0000.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.605 (s, 2H, 2-NH–), 4.811 (s, 4H, 2-CH2–), 7.940, 7.810 (s, 2H, 2 CH–), 2.324 (s, 6H, 2-CH3), 6.921, 6.935 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.489, 7.500 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.381 (t, J = 7.5 Hz, 1H, –NCH–), 7.974 (t, J = 7.5 Hz, 1H, –NCH–), 2.180 (q, J = 7.2 Hz, 4H, 2-CH2–), 1.460–1.500 (quintet, J = 7.3 Hz, 4H, 2-CH2–), 1.236–1.276 (sextet, J = 7.3 Hz, 4H. 2-CH2–), 0.839–0.903 (t, J = 7.5 Hz, 6H. 2-CH3).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 192.72, 169.39, 164.67, 162.33, 146.57, 142.55, 139.66, 139.51, 136.74, 129.96, 129.93, 127.68, 127.52, 127.36, 127.30, 127.25, 115.17, 114.99, 66.64, 64.85, 35.80, 30.81,24.80, 22.30, 18.40, 14.30.
HR-MS (EIMS): m/z [M + H]+ calcd for C26H34N4O4S: 498.6400, found: 498.0000.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.605 (s, 2H, 2-NH–), 4.811 (s, 4H, 2-CH2–), 7.940, 7.810 (s, 2H, 2 CH–), 2.324 (s, 6H, 2-CH3), 6.921, 6.935 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.489, 7.500 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.381 (t, J = 7.5 Hz, 1H, –NCH–), 7.974 (t, J = 7.5 Hz, 1H, –NCH–), 2.180 (q, J = 7.2 Hz, 4H, 2-CH2–), 1.460–1.500 (quintet, J = 7.3 Hz, 4H, 2-CH2–), 1.236–1.276 (sextet, J = 7.3 Hz, 4H. 2-CH2–), 0.839–0.903 (t, J = 7.5 Hz, 6H. 2-CH3).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 169.52, 164.85, 162.33, 157.37, 147.98, 147.82, 145.52, 141.54, 140.47, 140.32, 132.71, 128.11, 127.95, 127.36, 127.26, 124.08, 124.02, 115.16, 114.99, 66.60.64.85, 35.81, 30.80, 28.70, 26.80, 14.30.
HR-MS (EIMS): m/z [M + H]+ calcd for C24H30N4O4S: 470.5900, found: 470.0000.
1H NMR (DMSO-d6, 600.150 MHz, δ ppm): 11.632 (s, 2H, 2-NH–), 4.812 (s, 4H, 2-CH2–), 7.940, 7.810 (s, 2H, 2 CH–), 2.324 (s, 6H, 2-CH3), 6.896, 6.990 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.386, 7.459 (d, d, J = 8.2 Hz, 4H, Ar–H), 7.648 (t, J = 7.5 Hz, 1H, –NCH–), 6.928 (t, J = 7.5 Hz, 1H, –NCH–), 2.232–2.243 (q, J = 7.2 Hz, 4H, 2-CH2–), 1.223–1.531 (heptet, J = 7.3 Hz, 4H. 2-CH2–), 0.863–0.915 (t, J = 7.5 Hz, 6H. 2-CH3).
13C NMR (600.150 MHz, DMSO-d6): (δ ppm): 168.95, 164.18, 157.50, 157.43, 156.96, 150.83, 150.60, 148.03, 143.94, 133.16, 132.66, 132.50, 131.84, 131.72, 127.38, 127.33, 127.29, 127.26, 127.05, 126.83, 126.78, 115.16, 114.93, 66.66, 64.81, 33.40, 33.38, 23.68, 20.20, 18.80.
Finally, two mixes were made with 5 mL each of AChE (0.03 g mL−1) and BChE (0.01 g mL−1). The sample chemical was added to each combination in amounts ranging from 125 to 1000 g mL−1 along with DNTB (5 μL), and each mixture was then incubated for 15 minutes at 30 °C. 5 μL of substrates were then added to each mixture after the incubation period, and the reaction was then observed using a UV-Visible spectrophotometer for 4 minutes at 412 nm. The mixture took on a yellow hue, which was an indication that the 5-thio-2-nitrbenzoate anion was formed as a consequence of the interaction between the thiocholines and the DNTB. A control reaction mixture without enzymes and samples was also looked at to investigate the non-enzymatic hydrolysis of the substrate. Using the supplied formulae, enzyme activity and percent inhibition were computed.
% Age enzyme activity = 100 − % enzyme activity |
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d3ra03908k |
This journal is © The Royal Society of Chemistry 2023 |